Watch for partnership announcements for PDS0101 within the one-year exclusive negotiation window with NantWorks, and for Phase 3 development plans for PDS0101 and clinical updates on PDS0301 in mCRC.
Price Chart
Executive Summary
PDS Biotech announced the publication of Phase 2 VERSATILE-002 trial results for PDS0101 in combination with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer in JAMA Oncology. The data showed a median overall survival of 39.3 months in ICI-naive patients versus 17.9 months for standard-of-care pembrolizumab, and a 36% objective response rate versus 19% for pembrolizumab alone. The company is prioritizing PDS0301 in mCRC while pursuing a partnership for PDS0101, and recently closed a PIPE financing of up to $22.3 million led by Nant Capital with a one-year exclusive negotiation right for PDS0101.
Key Facts
- Phase 2 VERSATILE-002 results published in JAMA Oncology for PDS0101 + pembrolizumab in HPV16-positive R/M HNSCC
- Median overall survival of 39.3 months in ICI-naive patients (n=53) vs 17.9 months for standard-of-care pembrolizumab
- Objective response rate of 36% (investigator review) vs 19% for pembrolizumab alone
- Well-tolerated with 13.8% Grade ≥3 TRAEs vs 17% for pembrolizumab alone
- Company prioritizing PDS0301 in mCRC while pursuing partnership for PDS0101
- Recently closed PIPE financing of up to $22.3 million led by Nant Capital with one-year exclusive negotiation right for PDS0101
Financial Impact
Up to $22.3 million PIPE financing closed; partnership value for PDS0101 undisclosed
Risk Factors
- Phase 2 data is non-randomized and not head-to-head vs standard of care
- PDS0101 requires external partnership for Phase 3 development — no guarantee of favorable terms
- Company is clinical-stage with no approved products and relies on financing for operations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-037298 |
| Document: ef20082545_ex99-1.htm | 0001140361-26-037298 |
| Document: 0001140361-26-037298-index-headers.html | 0001140361-26-037298 |
| Document: 0001140361-26-037298-index.html | 0001140361-26-037298 |
| Document: 0001140361-26-037298.txt | 0001140361-26-037298 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 3 | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.07 (−14.11%) |
Oct 20, 2026 6d ago | 8-K | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.07 (−14.11%) |
Oct 20, 2026 6d ago | 8-K | $0.9605 $1.24 | ▲ +29.10% | ▲ +28.57% | $1.07 (+10.88%) |
Oct 14, 2026 12d ago | S-3 | $1.30 $1.13 | ▲ +13.08% | ▲ +11.97% | $1.07 (+18.08%) |
Oct 6, 2026 20d ago | 8-K | $1.05 $1.07 | ▲ +1.91% | ▲ +2.15% | $1.07 (+1.91%) |
Sep 22, 2026 4w ago | 8-K | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.07 (+17.03%) |
Sep 22, 2026 4w ago | Press Release | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.07 (+17.03%) |
Sep 21, 2026 5w ago | SC 13D | $0.9100 $0.8240 | ▼ −9.45% | ▼ −8.73% | $1.07 (+17.03%) |
Sep 4, 2026 7w ago | 8-K | $0.3000 $0.2930 | ▲ +2.33% | ▲ +1.87% | $1.07 (−255.00%) |
Aug 19, 2026 9w ago | 8-K | $0.2089 $0.2185 | ▲ +4.60% | ▲ +4.19% | $1.07 (+409.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers